HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hirst, B H Articles by Sanders, D J Search for Related Content PubMed PubMed Citation Articles by Hirst, B H Articles by Sanders, D J

The gastric-acid secretory potency of gastrin peptides was investigated in vivo, in conscious cats prepared with gastric fistula, and in vitro, with kitten isolated gastric mucosae. The influence of peptide length on potency was investigated by comparing synthetic human gastrin heptadecapeptide, non-sulphate (shG17ns) with a synthetic gastrin butyloxycarbonyl hexapeptide (G6ns), and the influence of sulphation by comparison of G6ns with its sister sulphated peptide (G6s). When exogenous doses were compared, shG17ns was the most potent peptide (mean exogenous dose for half-maximal stimulation (EDe50) : 0.33 nmol kg-1 h-1), and was 15.8 times more potent than G6ns (EDe50:5.14 nmol kg-1 h-1). This potency ratio was reduced to 9.4 when circulating immunoreactive concentrations of the two peptides were compared (mean circulating concentration for half-maximal stimulation (EDc50) : shG17ns, 201 pM; G6ns, 1890 pM). The greater potency ratio when exogenous doses were compared was due to the greater metabolic clearance rate (m.c.r.) of the shorter gastrin (m.c.r.: shG17ns, 37 ml kg-1 min-1; G6ns, 121 ml kg-1 min-1). In vitro, shG17ns (mean concentration for half-maximal stimulation (EC50) : 1.99 nM) was 2.8 times more potent than G6ns (EC50: 5.57 nM). Sulphation of the hexapeptide increased its potency 3.6-fold when exogenous doses were compared (EDe50 G6s: 1.42 nmol kg-1 h-1). The greater potency of the sulphated peptide appeared to be due to its lower m.c.r. (20 ml kg-1 min-1), and was eliminated when circulating concentrations were compared; potency ratio G6ns: G6s, 1.1. We conclude that the increased potency of short gastrin peptides observed upon sulphation is likely to be due to increased resistance to metabolic clearance. Part of the increased potency observed with increasing peptide length can also be explained by increased resistance to clearance, but the small potency difference in vitro may reflect greater affinity for gastrin receptors.

This article has been cited by other articles:

				A. C. Paterson, G. S. Baldwin, and A. Shulkes Metabolism of recombinant progastrin in sheep Am J Physiol Endocrinol Metab, September 1, 2002; 283(3): E449 - E456. [Abstract] [Full Text] [PDF]

				C. P. Hansen, F. Stadil, and J. F. Rehfeld Metabolism and acid secretory effect of sulfated and nonsulfated gastrin-6 in humans Am J Physiol Gastrointest Liver Physiol, November 1, 2000; 279(5): G903 - G909. [Abstract] [Full Text] [PDF]

				C. P. Hansen, J. P. Goetze, F. Stadil, and J. F. Rehfeld The metabolism of gastrin-52 and gastrin-6 in pigs Am J Physiol Gastrointest Liver Physiol, September 1, 2000; 279(3): G552 - G560. [Abstract] [Full Text] [PDF]